SR-29065 is a selective REV-ERBalpha agonist that inhibits BMAL1 transcription within the circadian transcription-translation feedback loop, and it has been applied to evaluate whether targeting both negative regulatory limbs of circadian control yields synergistic anti-tumor effects in glioblastoma models, supporting its broader use in autoimmune disorder and circadian rhythm research.
Molekulargewicht:
518.52
Reinheit:
97.24%
CAS Nummer:
[2756883-91-5]
Formel:
C24H24F6N2O2S
Target-Kategorie:
Nuclear receptor
T81107
* Mehrwertsteuer und Versandkosten nicht enthalten. Irrtümer und Preisänderungen vorbehalten
